BackLineage Cell Therapeutics Overview

Lineage Cell Therapeutics Inventory

Track Lineage Cell Therapeutics's inventory ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$0.00

Peer trimmed avg / median

Loading

Lineage Cell Therapeutics Inventory History

Loading

Lineage Cell Therapeutics vs. peers: Inventory Comparison

Loading

Lineage Cell Therapeutics Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Lineage Cell Therapeutics (LCTX) FAQ

As of the most recent data (June 2026), LCTX shows a inventory of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LCTX's inventory is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Lineage Cell Therapeutics is outperforming or lagging.

Tracking LCTX's inventory over time shows whether Lineage Cell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this inventory page, Stockcircle has Lineage Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect inventory (currently $0) with ownership activity and broader fundamentals.

Lineage Cell Therapeutics's inventory is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.